Sanofi's Eczema Treatment Delivers Mixed Results Across Several Trials -- Market Talk

Dow Jones01-23 19:25

1124 GMT - Sanofi's eczema treatment amlitelimab showed mixed results across several trials, Jefferies analyst Michael Leuchten writes in a note. The good news for the French drugmaker is that amlitelimab could be more conveniently administered than similar drugs, and it met a primary U.S.-centric study goal, Leuchten says. The bad news is it missed EU-focused endpoints, and one trial failed to improve on results from a previous iteration, the analyst says. Certain results showed efficacy that falls short of other biologic medications, and more detailed data are needed to make a stronger assessment there, he adds. Sanofi shares are down 1% at 78.95 euros.(william.gray@wsj.com)

(END) Dow Jones Newswires

January 23, 2026 06:25 ET (11:25 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605347450?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605347450","market":"fut","top_or_hot":-1,"title":"Sanofi's Eczema Treatment Delivers Mixed Results Across Several Trials -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1124 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s eczema treatment amlitelimab showed mixed results across several trials, Jefferies analyst Michael Leuchten writes in a note. The good news for the French drugmaker is that amlitelimab could be more conveniently administered than similar drugs, and it met a primary U.S.-centric study goal, Leuchten says. The bad news is it missed EU-focused endpoints, and one trial failed to improve on results from a previous iteration, the analyst says. Certain results showed efficacy that falls short of other biologic medications, and more detailed data are needed to make a stronger assessment there, he adds. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> shares are down 1% at 78.95 euros.(william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2026 06:25 ET (11:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Eczema Treatment Delivers Mixed Results Across Several Trials -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Eczema Treatment Delivers Mixed Results Across Several Trials -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-23 19:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1124 GMT - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>'s eczema treatment amlitelimab showed mixed results across several trials, Jefferies analyst Michael Leuchten writes in a note. The good news for the French drugmaker is that amlitelimab could be more conveniently administered than similar drugs, and it met a primary U.S.-centric study goal, Leuchten says. The bad news is it missed EU-focused endpoints, and one trial failed to improve on results from a previous iteration, the analyst says. Certain results showed efficacy that falls short of other biologic medications, and more detailed data are needed to make a stronger assessment there, he adds. <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> shares are down 1% at 78.95 euros.(william.gray@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2026 06:25 ET (11:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2605347450","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605347450","pubTimestamp":1769167500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1124 GMT - Sanofi's eczema treatment amlitelimab showed mixed results across several trials, Jefferies analyst Michael Leuchten writes in a note. The good news for the French drugmaker is that amlitelimab could be more conveniently administered than similar drugs, and it met a primary U.S.-centric study goal, Leuchten says. The bad news is it missed EU-focused endpoints, and one trial failed to improve on results from a previous iteration, the analyst says. Certain results showed efficacy that falls short of other biologic medications, and more detailed data are needed to make a stronger assessment there, he adds. Sanofi shares are down 1% at 78.95 euros.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念"},"translate_title":"赛诺菲的湿疹治疗在多项试验中取得了好坏参半的结果——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9,"SNYNF":1.5},"content_text":"1124 GMT - Sanofi's eczema treatment amlitelimab showed mixed results across several trials, Jefferies analyst Michael Leuchten writes in a note. The good news for the French drugmaker is that amlitelimab could be more conveniently administered than similar drugs, and it met a primary U.S.-centric study goal, Leuchten says. The bad news is it missed EU-focused endpoints, and one trial failed to improve on results from a previous iteration, the analyst says. Certain results showed efficacy that falls short of other biologic medications, and more detailed data are needed to make a stronger assessment there, he adds. Sanofi shares are down 1% at 78.95 euros.(william.gray@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 06:25 ET (11:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605347450","isCrawlerRequest":true}